Outcome
|
N studies
|
Population
|
Odds ratio (95%CI)
|
P value
|
H (95%CI)
|
I2 (95%CI)
|
P heterogeneity
|
P Harbord test
|
---|
SCD versus Control
|
VTE
|
3
|
Adults
|
4.43 (2.62–7.48)
|
<.0001
|
1.0 (1.0–2.8)
|
0.0 (0.0–87.3)
|
.440
|
.467
|
DVT
|
1
|
Adults
|
1.12 (1.09–1.15)
|
<.0001
|
NA
|
NA
|
NA
|
NA
|
PE
|
2
|
Adults
|
3.66 (3.57–3.75)
|
<.0001
|
1.0
|
0.0
|
0.588
|
NA
|
VTE
|
1
|
Pregnant and PP women
|
33.16 (9.70–113.37)
|
<.0001
|
NA
|
NA
|
NA
|
NA
|
DVT
|
1
|
Pregnant women
|
30.66 (1.63–578.15)
|
.022
|
NA
|
NA
|
NA
|
NA
|
SCD versus SCT
|
VTE
|
3
|
Adults
|
3.09 (1.79–5.33)
|
<.0001
|
1.0 (1.0–2.2)
|
0.0 (0.0–79.8)
|
.598
|
.524
|
PE
|
1
|
Adults
|
3.14 (1.67–5.92)
|
.0004
|
NA
|
NA
|
NA
|
NA
|
VTE
|
1
|
Pregnant and PP women
|
20.34 (4.05–102.05)
|
.0003
|
NA
|
NA
|
NA
|
NA
|
SCT versus Control
|
VTE
|
4
|
Adults
|
1.71 (1.34–2.18)
|
<.0001
|
1.0 (1.0–2.5)
|
0.0 (0.0–83.5)
|
.427
|
.238
|
DVT
|
3
|
Adults
|
1.23 (0.92–1.65)
|
.157
|
1.0 (1.0–1.5)
|
0.0 (0.0–55.7)
|
.791
|
.810
|
PE
|
3
|
Adults
|
2.12 (1.18–3.80)
|
.012
|
2.3 (1.3–4.0)
|
80.6 (39.0–93.8)
|
.006
|
.405
|
VTE
|
2
|
Pregnant and PP women
|
0.90 (0.28–2.89)
|
.863
|
1.48
|
47.5
|
0.168
|
NA
|
- CI confidence interval, DVT deep venous thrombosis, VTE venous thromboembolism, PE pulmonary embolism, PP postpartum, SCD, sickle cell disease, SCT sickle cell trait, NA not applicable